

Art Unit: 1642

Office Action of April 28, 2008 for record purposes.

DETAILED ACTION

1. The Amendment filed January 11, 2008 in response to the Office Action of October 11, 2007 is acknowledged and has been entered. Previously pending claims 6, 7 and 17 have been cancelled, claims 4, 5, and 8-10 have been amended
2. Claims 4, 5, and 8-10 are currently being examined.
3. The following rejections are being maintained:

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

4. Claims 4, 8, and 9 remain rejected under 35 USC 112, first paragraph for the reasons previously set forth in the Office Action of October 11, 2007, section 12-pages 13-19.

Applicants argue that with respect to the Examiner's assertion that the nucleic acid set forth in SEQ ID NO: 3 can code for a protein or polypeptide that is present in the nucleus of the animal cell, the nucleic acid set forth in SEQ ID NO: 3 can be present both in the nucleus and the cytoplasm.

Applicants argue that in order to assist the Examiner, claim 4, upon which claim 8 also depends, has been amended to define the nucleic acid recited in the claims as the nucleic acid set forth in SEQ ID NO: 3 and a nucleic acid strand that is completely complementary to the nucleic acid set forth in SEQ ID NO: 3. As acknowledged by the Examiner in the Office Action, the present application discloses SEQ ID NO: 3. The present application discloses that the term "nucleic acid of the present invention" can include a complementary strand selected from information of the nucleic acid set forth in SEQ ID NO: 3 (page 22). As is also acknowledged by

Art Unit: 1642

the Examiner, it is known in the art that the phrase "complementary strands of nucleic acids" can include nucleic acids that are completely complementary to the claimed polynucleotide.

Applicants arguments have been considered, but have not been found persuasive as the claims are still drawn to fragments of SEQ ID NO: 3. Claims 4, 7, and 9 are drawn to "A recombinant vector comprising **a purified nucleic acid coding for a** (emphasis added) protein or polypeptide . . . wherein the nucleic acid is set forth **in** (emphasis added) SEQ ID NO: 3 or is a nucleic acid that is completely complementary to the nucleic set forth **in** (emphasis added) SEQ ID NO: 3. . . ." and a host cell transformed with the vector and a method of producing the protein. This claim construction clearly reads on fragments of SEQ ID NO: 3 as the claims are not drawn to the protein or polypeptide produced from a nucleic acid comprising SEQ ID NO: 3. The claims are not enabled to make a fragment of SEQ ID NO: 3 that is present in the nucleus and which has a transcription factor function and/or a function that can induce expression of retinoblastoma gene or a gene product thereof, given that the specification has not identified the regions of the encoded polypeptide that are required for these functions and given the unpredictability of protein biochemistry and predicting function from structure previously set forth. Thus undue experimentation would be required to identify fragments that encode a protein with the claimed functions.

Applicant's arguments have not been found persuasive and the rejection is maintained.

5. Claims 4, 8 and 9 remain rejected under 35 USC 112, first paragraph for the reasons previously set forth in the Office Action of October 11, 2007, section, 13, pages 19-24.

Applicants argue that in order to assist the Examiner, claim 4, upon which claim 8 also depends, has been amended to define the nucleic acid recited in the claims as the nucleic acid set

Art Unit: 1642

forth in SEQ ID NO: 3 and a nucleic acid strand that is completely complementary to the nucleic acid set forth in SEQ ID NO: 3. As acknowledged by the Examiner in the Office Action, the present application discloses SEQ ID NO: 3. As is also acknowledged by the Examiner, it is known in the art that the phrase "complementary strands of nucleic acids" can include nucleic acids that are completely complementary to the claimed polynucleotide.

Applicants arguments have been considered, but have not been found persuasive as the claims are still drawn to fragments of SEQ ID NO: 3. Claims 4, 8 , and 9 are drawn to “A recombinant vector comprising **a purified nucleic acid coding for a** (emphasis added) protein or polypeptide . . . wherein the nucleic acid is set forth **in** (emphasis added) SEQ ID NO: 3 or is a nucleic acid that is completely complementary to the nucleic set forth **in** (emphasis added) SEQ ID NO: 3. . .” and a host cell transformed with the vector and a method of producing the protein. This claim construction clearly reads on fragments of SEQ ID NO: 3 as the claims are not drawn to the protein or polypeptide produced from a nucleic acid comprising SEQ ID NO: 3. Thus, the claims are not enabled to make a fragment of SEQ ID NO: 3 that is present in the nucleus and which has a transcription factor function and/or a function that can induce expression of retinoblastoma gene or a gene product thereof given that the specification has not identify the regions of the encoded polypeptide that are required for these functions and undue experimentation would be required to identify fragments that encode a protein with the claimed functions. The level of skill and knowledge in the art is such that one of ordinary skill would not be able to identify without further testing which of these fragment of SEQ ID NO: 3 can code for a protein have the ability to be present in the nucleus and which has a transcription factor function and/or a function that can induce expression of retinoblastoma gene or a gene product

Art Unit: 1642

thereof. Thus one of skill in the art would not recognize that Applicants were in possession of the claimed genus.

Applicant's arguments have not been found persuasive and the rejection is maintained.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

6. Claims 8-10 remain rejected and claims 4 and 5 are rejected under 35

U.S.C. 102(a) as being anticipated by Chano et al. (Oncogene, February 14, 2002, 21:1295-1298, IDS) for the reasons forth in the Office Action of October 11, 2007, section, 15, pages 25-27.

Applicants argue that three of the authors listed in Chano et al., Chano, Ikegawa, and Okabe, are the also the inventors of the present application. The remaining three authors listed in Chano et al., Kontani, Baldini, and Saeki, were working under the direction of the present inventors and their contributions were not of an inventive nature. Applicants submit herewith a Declaration under 37 C.F.R. § 1.132 to further establish that the authors of Chano et al. are the inventors of the present application. As such, Applicants respectfully submit that Chano et al. does not qualify as an invention known or used by "others" within the meaning of 35 U.S.C. §102(a).

The Declaration under 37 CFR 1.132 filed January 11, 2008 is insufficient to overcome the rejection of claims 4, 5 and 8-10 based upon Chano et al. (Oncogene, February 14, 2002, 21:1295-1298, IDS) as set forth in the last Office action because: The Declarants state in section 1:

We, Tokuhiro Chano, Shiro Ikegawa, and Hidetoshi Okabe, do declare and state as follows: **We are three of the six named inventors** (emphasis added) of the present application identified above.

Given the statement that “We are three of the six named inventors” and the identity of the other three inventors has not been made known to the Office nor have six inventors signed the Declaration, the Declaration under 37 CFR 1.132 is not an unequivocal statement from the Applicant regarding the subject matter disclosed in the article and has not properly executed, see MPEP 716.10 and CFR 1.63. Thus, the Declaration under 37 CFR 1.132 filed January 11, 2008 is insufficient to overcome the rejection.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

7. Claim 10 remains rejected under 35 U.S.C. 103(a) as being unpatentable over AB059622 (October 11, 2001), in view of Mensink et al (British J. Haematol. (August 1998) 102:768-774) and further in view of Buck et al (Biotechniques (1999) 27(3):528-536) for the reasons forth in the Office Action of October 11, 2007, section, 16, pages 28-30.

Applicants argue that as acknowledged by the Examiner, AB059622 does not teach the particular primers of SEQ ID Nos: 19 and 20. Mensink et al. and Buck et al. also do not, alone or in combination, teach or suggest SEQ ID Nos: 19 and 20. With reference to the Examiner's

Art Unit: 1642

assertion that published sequences may be analyzed by commercially available software for primer selection in many cases, one can use the "Primer 3 website" (primer3.sourceforge.net) for this purpose rather than the commercially available software taught in Mensink et al. Simply by knowing the nucleotide sequence information, one can use the "Primer 3 website" to analyze primer design with general versatility. However, only after using the designed primer, can one obtain useful information on whether or not it is applicable to an experiment or clinical. Thus, one cannot determine if a nucleotide sequence is useful, simply because the sequence is known. Accordingly, one of ordinary skill in the art would not be able to arrive at the particular primers of SEQ ID NOs: 19 and 20, simply because of the disclosure of AB059622.

Applicants arguments have been considered, but have not been found persuasive because of the availability in the art of primer design programs in the art at the time the invention was made and the teaching of Buck that every single primer tested of the 164 primers tested functioned as expected, one of skill in the art would have a reasonable expectation of success given that sequence was known in the art at the time the invention was made.

Applicant's arguments have not been found persuasive and the rejection is maintained.

New Grounds of Rejection

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

8. Claims 4, 5, and 8 are rejected under 35 U.S.C. 102(b) as being anticipated by Nagase et al. (DNA Research, 1996, 3:321-329) as evidenced by Nomura et al. (DNA Research,

Art Unit: 1642

1994: 1: 27-35), Chano et al. (Oncogene, February 14, 2002, 21:1295-1298, IDS) and Appendix 1.

The claims are drawn to:

4. A recombinant vector comprising a purified nucleic acid coding for a protein or polypeptide which is present in nucleus of human or animal cell and which has a transcription factor function and/or a function that can induce expression of retinoblastoma gene (RB 1 gene) or a gene product thereof the polypeptide or protein according to claim 1, or a complementary strand thereof, wherein the nucleic acid is set forth in SEQ ID No: 3 or is a nucleic acid strand that is completely complementary to the nucleic acid set forth in SEQ ID No: 3.

5. A recombinant vector comprising a nucleic acid hybridizing under stringent conditions with the a purified nucleic acid set forth in SEQ ID No: 3 or a nucleic acid strand that is completely complementary to the nucleic acid set forth in SEQ ID No: 3 according to claim 3 or the complementary strand thereof; wherein the stringent conditions comprise a condition under which a positive hybridization signal is still observed even after heating at 42 °C in a solution of 6 x SSC, 0.5% SDS and 50% formamide, and washing at 68 °C in a solution of 0.1 x SSC and 0.5% SDS.

8. A transformant that was transformed with the recombinant vector according to claim 4.

Nagase et al. teach the cloning of the cDNA KIAA0203, which 99.3% identical to SEQ ID NO: 3 and codes for a protein identical to RB1CC1, see Table 1 of Nagase et al. and Appendix 1. Nagase et al. used the methods Nomura et al. for cloning the cDNA, see Materials and Methods. and reference 1 of Nagase et al. Nomura et al. teach that cDNA were cloned and

Art Unit: 1642

placed into the pBluescript SK+ cDNA vector and used to make cDNA libraries that were grown in colonies of cells, see p. 28, 1st col., of Nomura et al.

Chano et al. teach that RB1CC1 can induce the expression of the RB1 gene, see Abstract, Fig. 2 and Fig.4.

Although the reference does not specifically state that KIAA0203 codes for a protein or polypeptide which is present in nucleus of human or animal cell and which has a transcription factor function and /or a function that can induce expression of retinoblastoma gene (RB1 gene) or a gene product thereof, given the teaching of Chano et al. The claimed product appears to be the same as the prior art product, absent a showing of unobvious differences. The office does not have the facilities and resources to provide the factual evidence needed in order to establish that the product of the prior art does not possess the same material, structural and functional characteristics of the claimed product. In the absence of evidence to the contrary, the burden is on the applicant to prove that the claimed product is different from those taught by the prior art and to establish patentable differences. See *In re Best* 562F.2d 1252, 195 USPQ 430 (CCPA).

Claim Rejections - 35 USC § 103

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

Art Unit: 1642

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

9. Claims 4, 5, 8, and 9 are rejected under 35 U.S.C. 103(a) as being unpatentable over AB059622 (October 11, 2001) as evidenced by Chano et al. (Oncogene, February 14, 2002, 21:1295-1298, IDS), in view of US Patent No. 4,889,806 (Dec. 1989) and Sambrook et al (Molecular Cloning, A Laboratory Manual, Cold Spring Harbor, 1989, pp.16.3-4).

The claims are drawn to:

4. A recombinant vector comprising a purified nucleic acid coding for a protein or polypeptide which is present in nucleus of human or animal cell and which has a transcription factor function and/or a function that can induce expression of retinoblastoma gene (RB 1 gene) or a gene product thereof the polypeptide or protein according to claim 1, or a complementary strand thereof, wherein the nucleic acid is set forth in SEQ ID No: 3 or is a nucleic acid strand that is completely complementary to the nucleic acid set forth in SEQ ID No: 3.

5. A recombinant vector comprising a nucleic acid hybridizing under stringent conditions with the a purified nucleic acid set forth in SEQ ID No: 3 or a nucleic acid strand that is completely complementary to the nucleic acid set forth in SEQ ID No: 3 according to claim 3 or the complementary strand thereof; wherein the stringent conditions comprise a condition

Art Unit: 1642

under which a positive hybridization signal is still observed even after heating at 42 °C in a solution of 6 x SSC, 0.5% SDS and 50% formamide, and washing at 68 °C in a solution of 0.1 x SSC and 0.5% SDS.

8. A transformant that was transformed with the recombinant vector according to claim 4.

9. A method for producing a protein or polypeptide which is present in the nucleus of a human or animal cell and which has a transcription factor function and/or a function that can induce expression of retinoblastoma gene (RB 1 gene) or a gene product thereof or a complementary strand thereof, wherein the nucleic acid is set forth in SEQ ID NO" 3 the polypeptide or protein according to claim 1 , comprising a step of culturing the transformant according to claim 8 with the recombinant vector containing nucleic acid coding for the polypeptide or protein.

AB059622 teaches as previously set forth in the Office Action of October 11, 2007, section 14, pages 24-25, but does not teach a recombinant vector comprising SEQ ID NO: 3, a transformant transformed with the recombinant vector, or a method for producing protein using the recombinant vector.

US Patent No. 4,889,806 teach that with the advent of recombinant DNA and molecular cloning technology it is now conventional to transfer genetic information into plasmids or vectors constructed in vitro and then transferred into host cells and clonally propagated (col. 1, lines 18-24).

Sambrook et al teach that cloned genes are conventionally expressed using expression vectors and that expression of cloned proteins have been used to: (1) confirm the identity of a cloned gene by using immunological or functional assays to detect the encoded protein; (2)

Art Unit: 1642

produce large amounts of proteins of biological interest that are normally available in only limited quantities from natural sources; (3) to study the biosynthesis and intracellular transport of proteins following their expression in various cell types; and (4) to elucidate structure-function relationships by analyzing the properties of normal and mutant proteins (para bridging pages 16.3 and 16.4).

It would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made to make a recombinant vector with the nucleic acid sequence of AB059622, transform the vector into a host cell and produce a protein with the methods of Sambrook et al and US Patent No. 4,889,806 because US Patent No. 4,889,806 specifically teaches that it is conventional to transfer genetic materials into plasmids or vectors and then transfer the plasmids or vectors into host cells and clonally propagate the genetic material and because Sambrook et al teach that cloned genes are conventionally expressed using expression vectors.

One of ordinary skill in the art at the time the invention was made would have been motivated to make a recombinant vector with the nucleic acid sequence of AB059622 with the methods of Sambrook et al and US Patent No. 4,889,806 because Sambrook et al specifically teach that expressed cloned proteins are used to: (1) confirm the identity of a cloned gene by using immunological or functional assays to detect the encoded protein; (2) produce large amounts of proteins of biological interest that are normally available in only limited quantities from natural sources; (3) to study the biosynthesis and intracellular transport of proteins following their expression in various cell types; and (4) to elucidate structure-function relationships by analyzing the properties of normal and mutant proteins. Given the conventional nature of the methods, one of skill in the art would have had a reasonable expectation of success.

Priority

10. Applicants state that at page 2, item 6, of the Office Action, the Examiner has acknowledged receipt of papers submitted under 35 U.S.C. § 119(a)-(d), which papers have been placed of record in the file. The Examiner recognizes a priority date of January 30, 2003. The Examiner indicates that because the priority of the instantly claimed invention is based on Japanese Application Nos. 2002-161400 and 2002-214978, and translations have not been provided, the Examiner is unable to recognize an earlier priority date. The Examiner suggests that Applicants submit a translation of the priority documents and to point to page and line where support can be found establishing an earlier priority date.

Applicants argue that English translations are not required for claiming priority. According to MPEP § 201.15, the actual merits of an applicant's claim of priority is considered by the Examiner only when a reference is found with an effective date between the date of the foreign filing and the date of filing in the United States. None of the publication dates of the references cited by the Examiner appears to fall within this range. As such, the priority dates of the Japanese applications should be recognized.

Applicants' arguments have been considered and the conditions for foreign priority Japanese Application Nos. 2002-161400 and 2002-214978 have been met.

11. All other objections and rejections recited in Office Action of October 11, 2007 are withdrawn.

12. No claims allowed.

13. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Peter J. Reddig whose telephone number is (571) 272-9031.

The examiner can normally be reached on M-F 8:30 a.m.-5:00 p.m.

Art Unit: 1642

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Larry Helms can be reached on (571) 272-0832. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Peter J Reddig/

Examiner, Art Unit 1642

/P. J. R./

/Karen A Canella/

Primary Examiner, Art Unit 1643

Appendix 1

```
D86958
LOCUS      D86958                6614 bp    mRNA    linear    PRI 15-JAN-2004
DEFINITION Homo sapiens mRNA for KIAA0203 gene, partial cds.
ACCESSION  D86958
VERSION    D86958.1  GI:1503989
KEYWORDS   .
SOURCE     Homo sapiens (human)
  ORGANISM Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
```

Art Unit: 1642

REFERENCE 1 Catarrhini; Hominidae; Homo.

AUTHORS Nagase,T., Seki,N., Ishikawa,K., Ohira,M., Kawarabayasi,Y., Ohara,O., Tanaka,A., Kotani,H., Miyajima,N. and Nomura,N.

TITLE Prediction of the coding sequences of unidentified human genes. VI. The coding sequences of 80 new genes (KIAA0201-KIAA0280) deduced by analysis of cDNA clones from cell line KG-1 and brain

JOURNAL DNA Res. 3 (5), 321-329 (1996)

PUBMED 9039502

REFERENCE 2 (bases 1 to 6614)

AUTHORS Ohara,O., Nagase,T., Kikuno,R. and Nomura,N.

TITLE Direct Submission

JOURNAL Submitted (02-AUG-1996) Osamu Ohara, Kazusa DNA Research Institute; 1532-3, Yana, Kisarazu, Chiba 292-0812, Japan (E-mail:cdnainfo@kazusa.or.jp, Tel:+81-438-52-3913)

FEATURES

source Location/Qualifiers

1. .6614

/organism="Homo sapiens"

/mol_type="mRNA"

/db_xref="taxon:9606"

/chromosome="8"

/sex="male"

/cell_line="KG-1"

/cell_type="myeloblast"

gene <1. .6614

/gene="KIAA0203"

5'UTR 1. .515

/gene="KIAA0203"

CDS <510. .5291

/gene="KIAA0203"

/note="Start codon is not identified similar to mouse CC1."

/citation=[1]

/codon_start=1

/protein_id="BAA13194.2"

/db_xref="GI:40788906"

/translation="IIMKLYVFLVNTGTTLTFTDTELTVQTVADLKHAIQSKYKIAIQH QVLVNGGECMAADRRVCTYSAGTDTNPILFNKEMILCDRPPAIPKTTTFSTENDMEI KVEESLMMPAVFHTVASRTQLALEMYEVAKKLCSEGLVHDEHLQHGWAAIMANLE DCSNSYQKLLFKFESIYSNYLQSIEDIKLLTHLGTAVSVMAKIPLECLTRHSYREC LGRDLSLPEHEDSEKAETKRSTELVLSPPDMPRTTNESSLTSFPKSVHEVSPDTADAE S GKEIRESQSTVHQDDETTIDTKDGDLPFFNVSLLDWINVQDRPNDESLSVRKCFDSM SRLDPRIIRPFIAECRQTIAKLDNQNMKAIKGLEDRLYALDQMIASCGRLVNEQKELA QGFLANQKRAENLKDASVLPDLCLSHANQLMIMLQNRKLLDIKQKCTTAKQELANNL HVRWKWCCFVMLHADQDGEKLQALLRLVIELLERVKIVEALSTVPQMYCLAVVEVVR KMFIKHYREWAGALVKDGRLYEAEKSKRESFGKLFRKSFRLNRLFRGLDSWPPSFCT QKPRKFDCLEPDISLKDQLFLQSFQSEVQPFRLVPLLCDFEPLHQHVLALHNLVKAA QSLDEMSQTITDLLSEQKASVSQTSPPQSASSPRMESTAGITTTSPRTPPPLTVQDPL CPAVCPLEELSPDSIDAHTFDFETIPHPNIEQTIHQVSLDLSLAESPESDFMSAVNE FVIEENLSSPNPISDPQSPPEMMVESLYSSVINAIDSRMQDTNVCCKEDFGDHTSLNV QLERCRVVAQDSHFSIQTIKEDLCHFRTFVQKEQCDFSNLCKTAVEIRNIEKVKCS LEITLKEKHQKELLSLKNEYEGKLDGLIKETEENENKIKKLGELVCLEEVQLQNKDNE FALVKHEKEAVICLQNEKDQKLEMEMNIMHSQNCIEKELKQGREIVLEDLKKLHVND EKLQLLRAELQSLQSHLKELEDTLQVRHIQEFQKVMTDHRSVLEELKKENQQIINQI QESHAEIIQEKEKQLQELKLVSDLSDRCKLEVEALKEAETDEIKILLEESRAQQK ETLKSLLEQETENLRTEISKLNQKIQDNNENYQVGLAELRLMTIEKQDCISELISRH BEESNILKAELENKVTSLHNQAFEIEKNLKEQIIELQSKLDSLSALERQKDEKITQQE EKYEAIQNLEKDRQKLVSSQEQQDREQLIQKLNCEKDEAIQTALKEFKLEREVVEKE LLEKVKHLENQIAKSPADSTRGDSSSLVAELQEKLEKAKFLEQLLEEQEKRNEMQ NVRTSLIAEQQTNTFNTVLTREKMRKENIINDLSDKLKSTMQQERDKDLIESLSEDR RLLLEKKKLEEEVSKLRSSSFVSPYVATAPELYGACAPELPGESDRSAVETADEGRV DSAMETSMMSVQENIHMLSEKQRIIMLLERTLQLKEENKRLNQRLMSQSMSSVSSRH SEKIAIRDFQVGDVLVLIILDERHDNYVLFVTSPTLYFLHSESLPALDLKPASGASRRP WVLGKVMKEYCQAKKAQNRFKVPPLGTFYRVKAVSWNKKV"

3'UTR 5292. .6614

/gene="KIAA0203"

ORIGIN

Art Unit: 1642

Query Match 99.3%; Score 6587; DB 5; Length 6614;
Best Local Similarity 99.8%; Pred. No. 0;
Matches 6609; Conservative 0; Mismatches 5; Indels 9; Gaps 1;

```
Qy      10 AACAAACCAAGCCGCGCGGTGTCCGCGGCCCTGCCGAGCCCTCGGCGTTGCCTCAGAAT 69
      |||
Db       1 AACAAACCAAGCCGCGCGGTGTCCGCGGCCCTGCCGAGCCCTCGGCGTTGCCTCAGAAT 60

Qy      70 CCCCCAGTCGCCTGGGCCCTCGGCTCTGACAGGCCGCGGCCTTCTGTCCCCGGCCCCA 129
      |||
Db       61 CCCCCAGTCGCCTGGGCCCTCGGCTCTGACAGGCCGCGGCCTTCTGTCCCCGGCCCCA 120

Qy     130 GACCAGAGCCGAGGGGCCTGCTCGCTCCTTGTCGCCCGGACCCCTCCCTGCCTCCTA 189
      |||
Db     121 GACCAGAGCCGAGGGGCCTGCTCGCTCCTTGTCGCCCGGACCCCTCCCTGCCTCCTA 180

Qy     190 GAGTTCGGGGCCGCGGCGGGCGGCCGGGACGCCGCGGTTGTGTGGCTTAGCGGT 249
      |||
Db     181 GAGTTCGGGGCCGCGGCGGGCGGCCGGGACGCCGCGGTTGTGTGGCTTAGCGGT 240

Qy     250 GCCGAATGGGCGGTTGGTAACCGTGCCGAGGACTAGGCGGCGGCGGAAGATGGTGCCGG 309
      |||
Db     241 GCCGAATGGGCGGTTGGTAACCGTGCCGAGGACTAGGCGGCGGCGGAAGATGGTGCCGG 300

Qy     310 GGGTCGCTGGCTCTGCTGCTGCCGCCGGCGAAGGAGGAGGCGTTGCCGGTTTTCTGAGTT 369
      |||
Db     301 GGGTCGCTGGCTCTGCTGCTGCCGCCGGCGAAGGAGGAGGCGTTGCCGGTTTTCTGAGTT 360

Qy     370 TAACCAGTAATGCCATTGAGTTGCCAATCTCAAGCAAAGCAAACATAAGCCAGTTTTAAT 429
      |||
Db     361 TAACCAGTAATGCCATTGAGTTGCCAATCTCAAGCAAAGCAAACATAAGCCAGTTTTAAT 420

Qy     430 CTACTTTTTAAGAAAAGTGGTAGTCCTTTTCACAGTGCCTGACGTAACGTATCAGAGGG 489
      |||
Db     421 CTACTTTTTAAGAAAAGTGGTAGTCCTTTTCACAGTGCCTGACGTAACGTATCAGAGGG 480

Qy     490 TGAGGTATAAGCTCACAGAATTCAGATAAATCATCATGAAGTTATATGTATTTCTGGTTA 549
      |||
Db     481 TGAGGTATAAGCTCACAGAATTCAGATAAATCATCATGAAGTTATATGTATTTCTGGTTA 540

Qy     550 AACTGGAACACTCTAACATTTGACACTGAACTTACAGTGCAAACGTGGCAGACCTTA 609
      |||
Db     541 AACTGGAACACTCTAACATTTGACACTGAACTTACAGTGCAAACGTGGCAGACCTTA 600

Qy     610 AGCATGCCATTCAAAGCAAATACAAGATTGCTATTCAACACCAGGTGCTGGTGGTCAATG 669
      |||
Db     601 AGCATGCCATTCAAAGCAAATACAAGATTGCTATTCAACACCAGGTGCTGGTGGTCAATG 660

Qy     670 GAGGAGAATGCATGGCTGCAGATCGAAGAGTGTGTACCTACAGTGCTGGGACGGATACAA 729
      |||
Db     661 GAGGAGAATGCATGGCTGCAGATCGAAGAGTGTGTACCTACAGTGCTGGGACGGATACAA 720

Qy     730 ATCCAATTTTTCTTTTAAACAAAGAAATGATCTTATGCGATCGTCCACCTGCTATTCCTA 789
      |||
Db     721 ATCCAATTTTTCTTTTAAACAAAGAAATGATCTTATGTGATCGTCCACCTGCTATTCCTA 780

Qy     790 AAACACCTTTTCGACAGAAAATGACATGGAAATAAAAGTTGAAGAATCTCTTATGATGC 849
      |||
Db     781 AAACACCTTTTCGACAGAAAATGACATGGAAATAAAAGTTGAAGAATCTCTTATGATGC 840

Qy     850 CTGCAGTTTTTCATACTGTTGCTTCAAGGACACAGCTTGCAATTGGAAATGTATGAAGTTG 909
      |||
Db     841 CTGCAGTTTTTCATACTGTTGCTTCAAGGACACAGCTTGCAATTGGAAATGTATGAAGTTG 900

Qy     910 CCAAGAACTTTGTTCTTTTGTGAAGGTCTTGTACATGATGAACATCTTCAACACCAAG 969
      |||
```

Art Unit: 1642

Db 901 CCAAGAACTTTGTTCTTTTGTGAAGGTCCTGTACATGATGAACATCTTCAACACCAAG 960

Qy 970 GCTGGGCTGCAATCATGGCCAACCTGGAGGACTGTTCAAATTCATACCAAAAAGCTACTTT 1029
|||||

Db 961 GCTGGGCTGCAATCATGGCCAACCTGGAGGACTGTTCAAATTCATACCAAAAAGCTACTTT 1020

Qy 1030 TCAAGTTTGAAAGTATTTATTCAAATTATCTGCAGTCCATAGAAGACATCAAGTTAAAAC 1089
|||||

Db 1021 TCAAGTTTGAAAGTATTTATTCAAATTATCTGCAGTCCATAGAAGACATCAAGTTAAAAC 1080

Qy 1090 TTACTCATTTAGGAACTGCAGTTTCAGTAATGGCCAAGATTCCACTGTTGGAGTGCCTAA 1149
|||||

Db 1081 TTACTCATTTAGGAACTGCAGTTTCAGTAATGGCCAAGATTCCACTGTTGGAGTGCCTAA 1140

Qy 1150 CCAGACATAGTTACAGAGAATGTTTGGGAAGACTGGATTCTTTACCTGAACATGAAGACT 1209
|||||

Db 1141 CCAGACATAGTTACAGAGAATGTTTGGGAAGACTGGATTCTTTACCTGAACATGAAGACT 1200

Qy 1210 CAGAAAAAGCTGAGACGAAAAGATCCACTGAACTGGTGTCTCTCCTGATATGCCTAGAA 1269
|||||

Db 1201 CAGAAAAAGCTGAGACGAAAAGATCCACTGAACTGGTGTCTCTCCTGATATGCCTAGAA 1260

Qy 1270 CAACTAACGAATCTTTGTTAACCTCATTTCCCAAGTCAGTGGAAACATGTGTCCCAGATA 1329
|||||

Db 1261 CAACTAACGAATCTTTGTTAACCTCATTTCCCAAGTCAGTGGAAACATGTGTCCCAGATA 1320

Qy 1330 CCGCAGATGCTGAAAGTGGCAAAGAAATTAGGGAATCTTGTCAAAGTACTGTTTCATCAGC 1389
|||||

Db 1321 CCGCAGATGCTGAAAGTGGCAAAGAAATTAGGGAATCTTGTCAAAGTACTGTTTCATCAGC 1380

Qy 1390 AAGATGAACTACGATTGACACTAAAGATGGTGATCTGCCCTTTTTTAATGTCTCTTTGT 1449
|||||

Db 1381 AAGATGAACTACGATTGACACTAAAGATGGTGATCTGCCCTTTTTTAATGTCTCTTTGT 1440

Qy 1450 TAGACTGGATAAATGTTCAAGATAGACCTAATGATGTGGAATCTTTGGTCAGGAAGTGCT 1509
|||||

Db 1441 TAGACTGGATAAATGTTCAAGATAGACCTAATGATGTGGAATCTTTGGTCAGGAAGTGCT 1500

Qy 1510 TTGATTCTATGAGCAGGCTTGATCCAAGGATTATTCGACCATTATAGCAGAATGCCGTC 1569
|||||

Db 1501 TTGATTCTATGAGCAGGCTTGATCCAAGGATTATTCGACCATTATAGCAGAATGCCGTC 1560

Qy 1570 AAATATTGCCAAACTTGATAATCAGAATATGAAAGCCATTAAGGACTTGAAGATCGGC 1629
|||||

Db 1561 AAATATTGCCAAACTTGATAATCAGAATATGAAAGCCATTAAGGACTTGAAGATCGGC 1620

Qy 1630 TCTACGCCCTGGACCAGATGATTGCTAGCTGTGGCCGACTGGTGAATGAACAGAAAGAGC 1689
|||||

Db 1621 TCTACGCCCTGGACCAGATGATTGCTAGCTGTGGCCGACTGGTGAATGAACAGAAAGAGC 1680

Qy 1690 TTGCTCAGGGATTTTAGCTAATCAGAAGAGAGCTGAAAACCTAAAGGATGCATCTGTAT 1749
|||||

Db 1681 TTGCTCAGGGATTTTAGCTAATCAGAAGAGAGCTGAAAACCTAAAGGATGCATCTGTAT 1740

Qy 1750 TACCTGATTTATGCCTGAGTCACGCAAAATCAGTTGATGATTATGTTGCAAAATCATAGAA 1809
|||||

Db 1741 TACCTGATTTATGCCTGAGTCACGCAAAATCAGTTGATGATTATGTTGCAAAATCATAGAA 1800

Qy 1810 AACTGTTAGATATTAAGCAGAAGTGTAACCACTGCCAAACAAGAACTAGCAAATAACCTAC 1869
|||||

Db 1801 AACTGTTAGATATTAAGCAGAAGTGTAACCACTGCCAAACAAGAACTAGCAAATAACCTAC 1860

Qy 1870 ATGTCAGACTGAAGTGGTGTGCTTTGTAATGCTTCATGCTGATCAAGATGGAGAGAAGT 1929
|||||

Db 1861 ATGTCAGACTGAAGTGGTGTGCTTTGTAATGCTTCATGCTGATCAAGATGGAGAGAAGT 1920

Qy 1930 TACAAGCTTTGCTCCGCCCTCGTAATAGAGCTGTTAGAAAGAGTCAAATTTGTTGAAGCTC 1989

Art Unit: 1642

```

Db      1921  |||TACAAAGCTTTGCTCCGCTCGTAATAGAGCTGTTAGAAAAGAGTCAAAATGTTGAAGCTC 1980
Qy      1990  |||TTAGTACAGTTCCTCAGATGTACTGCTTAGCTGTTGTTGAGGTTGTAAGAAGAAAAATGT 2049
Db      1981  |||TTAGTACAGTTCCTCAGATGTACTGCTTAGCTGTTGTTGAGGTTGTAAGAAGAAAAATGT 2040
Qy      2050  |||TCATAAAACACTACAGGGAGTGGGCTGGTGCTTTAGTCAAAGATGGAAGAGATTATATG 2109
Db      2041  |||TCATAAAACACTACAGGGAGTGGGCTGGTGCTTTAGTCAAAGATGGAAGAGATTATATG 2100
Qy      2110  |||AAGCAGAAAAATCAAAAAGGGAATCCTTTGGGAAATTATTTAGGAAGTCTTTTTTAAGAA 2169
Db      2101  |||AAGCAGAAAAATCAAAAAGGGAATCCTTTGGGAAATTATTTAGGAAGTCTTTTTTAAGAA 2160
Qy      2170  |||ATCGTCTGTTTAGGGGACTGGACTCCTGGCCCCCTTCCTTTTGTACTCAAAGCCTCGAA 2229
Db      2161  |||ATCGTCTGTTTAGGGGACTGGACTCCTGGCCCCCTTCCTTTTGTACTCAAAGCCTCGAA 2220
Qy      2230  |||AGTTTGACTGTGAACCTCCAGATATTTTCATTAAGATTACAGTTTCTGCAATCATTTT 2289
Db      2221  |||AGTTTGACTGTGAACCTCCAGATATTTTCATTAAGATTACAGTTTCTGCAATCATTTT 2280
Qy      2290  |||GTCCTTCGGAAGTTCAGCCATTCTCAGGGTTCCTTACTTTGTGACTTTGAACCTCTAC 2349
Db      2281  |||GTCCTTCGGAAGTTCAGCCATTCTCAGGGTTCCTTACTTTGTGACTTTGAACCTCTAC 2340
Qy      2350  |||ACCAGCATGTACTTGCTCTACATAATTTGGTAAAAGCAGCACAAAGTTTGGATGAAATGT 2409
Db      2341  |||ACCAGCATGTACTTGCTCTACATAATTTGGTAAAAGCAGCACAAAGTTTGGATGAAATGT 2400
Qy      2410  |||CACAGACCATTACAGATCTACTGAGTGAACAAAAGGCATCTGTGAGCCAGACATCCCCAC 2469
Db      2401  |||CACAGACCATTACAGATCTACTGAGTGAACAAAAGGCATCTGTGAGTCAAGACATCCCCAC 2460
Qy      2470  |||AGTCTGCTTCTTCACCAAGGATGGAAGTACAGCAGGAATTACAACACTACTACCTCACCGA 2529
Db      2461  |||AGTCTGCTTCTTCACCAAGGATGGAAGTACAGCAGGAATTACAACACTACTACCTCACCGA 2520
Qy      2530  |||GAACTCCTCCACCACTGACTGTTCCAGGATCCCTTATGTCCTGCAGTTTGTCCCTTAGAAG 2589
Db      2521  |||GAACTCCTCCACCACTGACTGTTCCAGGATCCCTTATGTCCTGCAGTTTGTCCCTTAGAAG 2580
Qy      2590  |||AATTATCTCCAGATAGTATTGATGCACATACGTTTGATTTTGAAACTATTCCCCATCCAA 2649
Db      2581  |||AATTATCTCCAGATAGTATTGATGCACATACGTTTGATTTTGAAACTATTCCCCATCCAA 2640
Qy      2650  |||ACATAGAACAGACTATTACCAAGTTTCTTTAGACTTGGAATTCATTAGCAGAAAGTCCTG 2709
Db      2641  |||ACATAGAACAGACTATTACCAAGTTTCTTTAGACTTGGAATTCATTAGCAGAAAGTCCTG 2700
Qy      2710  |||AATCAGATTTTATGCTGCTGTGAATGAGTTTGTAATAGAAGAAAATTTGTCGTCCTCTA 2769
Db      2701  |||AATCAGATTTTATGCTGCTGTGAATGAGTTTGTAATAGAAGAAAATTTGTCGTCCTCTA 2760
Qy      2770  |||ATCCTATAAGTGATCCACAAAGCCCAGAAATGATGGTGGAATCACTTTATTCATCAGTTA 2829
Db      2761  |||ATCCTATAAGTGATCCACAAAGCCCAGAAATGATGGTGGAATCACTTTATTCATCAGTTA 2820
Qy      2830  |||TCAATGCGATAGACAGTAGACGAATGCAGGATACAAATGTATGTGGTAAGGAGGATTTTG 2889
Db      2821  |||TCAATGCGATAGACAGTAGACGAATGCAGGATACAAATGTATGTGGTAAGGAGGATTTTG 2880
Qy      2890  |||GAGATCATACTTCTCTGAATGTCCAGTTGGAAAGATGTAGAGTTGTTGCCCCAAGACTCTC 2949
Db      2881  |||GAGATCATACTTCTCTGAATGTCCAGTTGGAAAGATGTAGAGTTGTTGCCCCAAGACTCTC 2940

```

Art Unit: 1642

Qy 2950 ACTTCAGTATACAAACCATTAAAGGAAGACCTTTGCCACTTTAGAACATTGTACAAAAAG 3009
|||||
Db 2941 ACTTCAGTATACAAACCATTAAAGGAAGACCTTTGCCACTTTAGAACATTGTACAAAAAG 3000

Qy 3010 AACAGTGTGACTTCTCAAATTCATTAAAAATGTACAGCAGTAGAAATAAGAAACATTATTG 3069
|||||
Db 3001 AACAGTGTGACTTCTCAAATTCATTAAAAATGTACAGCAGTAGAAATAAGAAACATTATTG 3060

Qy 3070 AAAAAGTAAATGTTCTCTGGAATAACACTAAAAGAAAAACATCAAAAAGAACTACTGT 3129
|||||
Db 3061 AAAAAGTAAATGTTCTCTGGAATAACACTAAAAGAAAAACATCAAAAAGAACTACTGT 3120

Qy 3130 CTTTAAAAAATGAATATGAAGGTAAACTTGACGGACTAATAAGGAAACTGAAGAGAATG 3189
|||||
Db 3121 CTTTAAAAAATGAATATGAAGGTAAACTTGACGGACTAATAAGGAAACTGAAGAGAATG 3180

Qy 3190 AAAACAAAATTAAAAAATTGAAGGGAGAGTTAGTATGCCTTGAGGAGGTTTACAAAATA 3249
|||||
Db 3181 AAAACAAAATTAAAAAATTGAAGGGAGAGTTAGTATGCCTTGAGGAGGTTTACAAAATA 3240

Qy 3250 AAGATAATGAATTTGCTTTGGTTAAACATGAAAAAGAAGCTGTAATCTGCCTGCAGAATG 3309
|||||
Db 3241 AAGATAATGAATTTGCTTTGGTTAAACATGAAAAAGAAGCTGTAATCTGCCTGCAGAATG 3300

Qy 3310 AAAAGGATCAGAAGTTGTTAGAGATGGAATAATAATGCACTCTCAAAATTGTGAAATTA 3369
|||||
Db 3301 AAAAGGATCAGAAGTTGTTAGAGATGGAATAATAATGCACTCTCAAAATTGTGAAATTA 3360

Qy 3370 AAGAACTGAAGCAGTCACGAGAAATAGTGTTAGAAGACTTAAAAAGCTCCATGTTGAAA 3429
|||||
Db 3361 AAGAACTGAAGCAGTCACGAGAAATAGTGTTAGAAGACTTAAAAAGCTCCATGTTGAAA 3420

Qy 3430 ATGATGAGAAGTTACAGTTATTGAGGGCAGAACTTCAGTCCTTGAGGCAAAGTCATCTAA 3489
|||||
Db 3421 ATGATGAGAAGTTACAGTTATTGAGGGCAGAACTTCAGTCCTTGAGGCAAAGTCATCTAA 3480

Qy 3490 AGGAATTAGAGGACACACTTCAGGTTAGGCACATACAAGAGTTTGAGAAGGTTATGACAG 3549
|||||
Db 3481 AGGAATTAGAGGACACACTTCAGGTTAGGCACATACAAGAGTTTGAGAAGGTTATGACAG 3540

Qy 3550 ACCACAGAGTTTCTTTGGAGGAATTAAGGAAATCAACAAATAATTAATCAAATAC 3609
|||||
Db 3541 ACCACAGAGTTTCTTTGGAGGAATTAAGGAAATCAACAAATAATTAATCAAATAC 3600

Qy 3610 AAGAATCTCATGCTGAAATTATCCAGGAAAAAGAAAAACAGTTACAGGAATTAAGAACTCA 3669
|||||
Db 3601 AAGAATCTCATGCTGAAATTATCCAGGAAAAAGAAAAACAGTTACAGGAATTAAGAACTCA 3660

Qy 3670 AGGTTTCTGATTTGTGACACAGAGATGCAAGTTAGAGGTTGAACTTGCCTTGAAGGAAG 3729
|||||
Db 3661 AGGTTTCTGATTTGTGACACAGAGATGCAAGTTAGAGGTTGAACTTGCCTTGAAGGAAG 3720

Qy 3730 CAGAACTGATGAAATAAAAAATTTTGCTGGAAGAAAGCAGAGCCAGCAGAAGGAGACCT 3789
|||||
Db 3721 CAGAACTGATGAAATAAAAAATTTTGCTGGAAGAAAGCAGAGCCAGCAGAAGGAGACCT 3780

Qy 3790 TGAAATCTCTTCTGAAACAAGAGACAGAAAAATTTGAGAACAGAAATTAGTAACTCAACC 3849
|||||
Db 3781 TGAAATCTCTTCTGAAACAAGAGACAGAAAAATTTGAGAACAGAAATTAGTAACTCAACC 3840

Qy 3850 AAAAGATTGAGGATAATAATGAAAATTATCAGGTGGGCTTAGCAGAGCTAAGAACTTTAA 3909
|||||
Db 3841 AAAAGATTGAGGATAATAATGAAAATTATCAGGTGGGCTTAGCAGAGCTAAGAACTTTAA 3900

Qy 3910 TGACAAATTGAAAAAGATCAGCGTATTTCCGAGTTAATTAGTAGACATGAAGAAGAATCTA 3969
|||||
Db 3901 TGACAAATTGAAAAAGATCAGTGATTTCCGAGTTAATTAGTAGACATGAAGAAGAATCTA 3960

Qy	3970	ATATACTTAAAGCTGAATTAAACAAAGTAACATCTTTGCATAACCAAGCATTGAAATAG	4029
Db	3961	ATATACTTAAAGCTGAATTAAACAAAGTAACATCTTTGCATAACCAAGCATTGAAATAG	4020
Qy	4030	AAAAAAACCTAAAAGAACAAATAATTGAACTGCAGAGTAAATTGGATTGAGAATTGAGTG	4089
Db	4021	AAAAAAACCTAAAAGAACAAATAATTGAACTGCAGAGTAAATTGGATTGAGAATTGAGTG	4080
Qy	4090	CTCTTGAAAGACAAAAGATGAAAAAATTACCCAACAAGAAGAGAAATACGAAGCTATTA	4149
Db	4081	CTCTTGAAAGACAAAAGATGAAAAAATTACCCAACAAGAAGAGAAATACGAAGCTATTA	4140
Qy	4150	TCCAGAACCTTGAGAAAGACAGACAAAAATTGGTCAGCAGCCAGGAGCAAGACAGAGAAC	4209
Db	4141	TCCAGAACCTTGAGAAAGACAGACAAAAATTGGTCAGCAGCCAGGAGCAAGACAGAGAAC	4200
Qy	4210	AGTTAATTGAGAAGCTTAATTGTGAAAAAGATGAAGCTATTGAGACTGCCCTAAAAGAAT	4269
Db	4201	AGTTAATTGAGAAGCTTAATTGTGAAAAAGATGAAGCTATTGAGACTGCCCTAAAAGAAT	4260
Qy	4270	TTAAATTGGAGAGAGAAGTTGTTGAGAAAGAGTTATTAGAAAAAGTTAAACATCTTGAGA	4329
Db	4261	TTAAATTGGAGAGAGAAGTTGTTGAGAAAGAGTTATTAGAAAAAGTTAAACATCTTGAGA	4320
Qy	4330	ATCAAAATAGCAAAAAGTCTGCCATTGACTCTACCAGAGGAGATTCTTCAAGCTTAGTTG	4389
Db	4321	ATCAAAATAGCAAAAAGTCTGCCATTGACTCTACCAGAGGAGATTCTTCAAGCTTAGTTG	4380
Qy	4390	CTGAACCTTCAAGAAAAGCTTCAGGAAGAAAAAGCTAAGTTTCTAGAACAACCTGAAGAGC	4449
Db	4381	CTGAACCTTCAAGAAAAGCTTCAGGAAGAAAAAGCTAAGTTTCTAGAACAACCTGAAGAGC	4440
Qy	4450	AAGAAAAAAGAAAGAATGAAGAAATGCAAAATGTTTCGAACATCTTTGATTGCGGAACAC	4509
Db	4441	AAGAAAAAAGAAAGAATGAAGAAATGCAAAATGTTTCGAACATCTTTGATTGCGGAACAC	4500
Qy	4510	AGACCAATTTTAAACACTGTTTTTAAACAAGAGAGAAAAATGAGAAAAGAAAACATAATAAATG	4569
Db	4501	AGACCAATTTTAAACACTGTTTTTAAACAAGAGAGAAAAATGAGAAAAGAAAACATAATAAATG	4560
Qy	4570	ATCTTAGTGATAAGTTGAAAAGTACAATGCAGCAACAAGAACGGGATAAAGATTTGATAG	4629
Db	4561	ATCTTAGTGATAAGTTGAAAAGTACAATGCAGCAACAAGAACGGGATAAAGATTTGATAG	4620
Qy	4630	AGTCACCTTTCTGAAGATCGAGCTCGTTTGCTTGAGGAAAAGAAAAAGCTTGAAGAAGAAG	4689
Db	4621	AGTCACCTTTCTGAAGATCGAGCTCGTTTGCTTGAGGAAAAGAAAAAGCTTGAAGAAGAAG	4680
Qy	4690	TCAGTAAGTTGCGCAGTAGCAGTTTTTGTTCCTTCACCATATGTAGCTACAGCCCCAGAAC	4749
Db	4681	TCAGTAAGTTGCGCAGTAGCAGTTTTTGTTCCTTCACCATATGTAGCTACAGCCCCAGAAC	4740
Qy	4750	TTTATGGAGCTTGTGCACCTGAACTCCCAGGTGAATCAGATAGATCCGCTGTGGAACAG	4809
Db	4741	TTTATGGAGCTTGTGCACCTGAACTCCCAGGTGAATCAGATAGATCCGCTGTGGAACAG	4800
Qy	4810	CAGATGAAGGAAGAGTGGATTGAGCAATGGAGACAAGCATGATGTCTGTACAAGAAAATA	4869
Db	4801	CAGATGAAGGAAGAGTGGATTGAGCAATGGAGACAAGCATGATGTCTGTACAAGAAAATA	4860
Qy	4870	TTCATATGTTGTCTGAAGAAAAACAGCGGATAATGCTGTTAGAACGAACATTGCAATTGA	4929
Db	4861	TTCATATGTTGTCTGAAGAAAAACAGCGGATAATGCTGTTAGAACGAACATTGCAATTGA	4920
Qy	4930	AAGAAGAAGAAAATAAACGGTTAAATCAAAGACTGATGTCTCAGAGCATGTCTTCAGTAT	4989

Art Unit: 1642

Db 4921 AAGAAGAAGAAAATAAACGGTTAAATCAAAGACTGATGTCTCAGAGCATGTCTTCAGTAT 4980

Qy 4990 CTTCAAGGCATTCTGAAAAGATAGCTATTAGAGATTTTCAGGTGGGAGATTGGTACTCA 5049
|||||

Db 4981 CTTCAAGGCATTCTGAAAAGATAGCTATTAGAGATTTTCAGGTGGGAGATTGGTACTCA 5040

Qy 5050 TCATCCTAGACGAACGCCATGACAATTATGTGTTATTTACTGTTAGTCCTACTTTATATT 5109
|||||

Db 5041 TCATCCTAGACGAACGCCATGACAATTATGTGTTATTTACTGTTAGTCCTACTTTATATT 5100

Qy 5110 TTCTACATTAGAGTCTCTACCTGCCCTGGATCTCAAACAGGTGAGGGTGCTTCAGGTG 5169
|||||

Db 5101 TTCTACATTAGAGTCTCTACCTGCCCTGGATCTCAAACCA-----GCTTCAGGTG 5151

Qy 5170 CATCTAGAAGACCCCTGGGTACTTGGAAAAGTAATGGAAGAAAGAACTACTGTCAAGCCAAAA 5229
|||||

Db 5152 CATCTAGAAGACCCCTGGGTACTCGGAAAAGTAATGGAAGAAAGAACTACTGTCAAGCCAAAA 5211

Qy 5230 AGGCACAAAACAGATTTAAAGTTCCTTTGGGGACAAAGTTTACAGAGTGAAAGCCGTAT 5289
|||||

Db 5212 AGGCACAAAACAGATTTAAAGTTCCTTTGGGGACAAAGTTTACAGAGTGAAAGCCGTAT 5271

Qy 5290 CATGGAATAAGAAAGTATAACTTATGGACAAAATTAATACATTCTATGACATTTTTTCT 5349
|||||

Db 5272 CATGGAATAAGAAAGTATAACTTATGGACAAAATTAATACATTCTATGACATTTTTTCT 5331

Qy 5350 GATTGTCTGCAGTGTCTCATTCACTCCAAAAACAGCAGGCCATCTTTTATGCAAA 5409
|||||

Db 5332 GATTGTCTGCAGTGTCTCATTCACTCCAAAAACAGCAGGCCATCTTTTATGCAAA 5391

Qy 5410 AGTCAGCGTGACAATATACTTCACTGGTGTACATCGTTTACTTTTTAACTGGCTTCATTT 5469
|||||

Db 5392 AGTCAGCGTGACAATATACTTCACTGGTGTACATCGTTTACTTTTTAACTGGCTTCATTT 5451

Qy 5470 TAGGAATAATAAATTCATCAGAATCCCTGGCTGAATTAATAAGTGGTTTTGTTTTGGTT 5529
|||||

Db 5452 TAGGAATAATAAATTCATCAGAATCCCTGGCTGAATTAATAAGTGGTTTTGTTTTGGTT 5511

Qy 5530 TTTTTTTTTACCCAGACAACTCTAGAAATGCGGACCAAACTACTTCATTTCTCAAAGGG 5589
|||||

Db 5512 TTTTTTTTTACCCAGACAACTCTAGAAATGCGGACCAAACTACTTCATTTCTCAAAGGG 5571

Qy 5590 CATACCTTTGTGCATTGTGGCTTATGATGAGCCATATTAATTGCCTGTTAAATATACACTA 5649
|||||

Db 5572 CATACCTTTGTGCATTGTGGCTTATGATGAGCCATATTAATTGCCTGTTAAATATACACTA 5631

Qy 5650 GCTTGAACCTTAGATGTTAAATGTTATTATTACCAGCATTGTCCTTTTGTGAAATCAGTA 5709
|||||

Db 5632 GCTTGAACCTTAGATGTTAAATGTTATTATTACCAGCATTGTCCTTTTGTGAAATCAGTA 5691

Qy 5710 TCAGAATACTTGCACTCTTTAACACATTCTTTATAAAATGTATAAATTATTCAGAACTAT 5769
|||||

Db 5692 TCAGAATACTTGCACTCTTTAACACATTCTTTATAAAATGTATAAATTATTCAGAACTAT 5751

Qy 5770 TTAAAAATAAGAGGAGTGTTATTGCATGCTGATAATCATTTTGAGTTTGCCTCAGTAGAT 5829
|||||

Db 5752 TTAAAAATAAGAGGAGTGTTATTGCATGCTGATAATCATTTTGAGTTTGCCTCAGTAGAT 5811

Qy 5830 ACTAAAGCAAATTGTTTCAGTTTTTTTAAATGCCCTTTGATGTTTCAAAAAAAAAAAGGA 5889
|||||

Db 5812 ACTAAAGCAAATTGTTTCAGTTTTTTTAAATGCCCTTTGATGTTTCAAAAAAAAAAAGGA 5871

Qy 5890 ACTGTAATTTGATTGACTGATTTTAAAGATCAGCCATAAGTAATCAGCAATCTTCAAAGC 5949
|||||

Db 5872 ACTGTAATTTGATTGACTGATTTTAAAGATCAGCCATAAGTAATCAGCAATCTTCAAAGC 5931

Qy 5950 ACTTTCAGTGGATTGGTCATCTGGGTTCTAAAGGAAGAGTCTGTGCTACTAACCATTTC 6009

Art Unit: 1642

```
|||||
Db      5932  ACTTTCAGTGGATTGGTCATCTGGGTTCTAAAGGAAGAGTCTGTGCTACTAACCATTTC 5991
Qy      6010  AAATGCAGACTCAAACCTTCCCAACATCTTTATGACTCTAGAATAATCATATTGATGAAA 6069
        |||||
Db      5992  AAATGCAGACTCAAACCTTCCCAACATCTTTATGACTCTAGAATAATCATATTGATGAAA 6051
Qy      6070  TCGTAATTCATGGTTGAGTTTCAGAACAAAAGATATTCATTGCACATTAACCATTTAGAG 6129
        |||||
Db      6052  TCGTAATTCATGGTTGAGTTTCAGAACAAAAGATATTCATTGCACATTAACCATTTAGAG 6111
Qy      6130  GTCATTTAAATAACAAAATATTGTATTGTAAAAGAACTGTACAATTTTAAACAATAAAG 6189
        |||||
Db      6112  GTCATTTAAATAACAAAATATTGTATTGTAAAAGAACTGTACAATTTTAAACAATAAAG 6171
Qy      6190  ATTTGAACCTGTAAATGTGTGTGCCTTTTAAAGAAGGATACATTTTAAATATATTGAGT 6249
        |||||
Db      6172  ATTTGAACCTGTAAATGTGTGTGCCTTTTAAAGAAGGATACATTTTAAATATATTGAGT 6231
Qy      6250  GATTGCTGGGAAGTGTGAAAATATTGTTATGTATCATATCAAAGAGAAACATGTTTATTA 6309
        |||||
Db      6232  GATTGCTGGGAAGTGTGAAAATATTGTTATGTATCATATCAAAGAGAAACATGTTTATTA 6291
Qy      6310  CAAAAATGTTCTTTAACTATATACTATGTAACAGGGTAAACAGTGTTATGTAGAATAGAA 6369
        |||||
Db      6292  CAAAAATGTTCTTTAACTATATACTATGTAACAGGGTAAACAGTGTTATGTAGAATAGAA 6351
Qy      6370  TTGTGTAACTAGATCTTTAGAGAAGTTGCCATTGAGCAAAGTTATTTAAATGAGTTAGT 6429
        |||||
Db      6352  TTGTGTAACTAGATCTTTAGAGAAGTTGCCATTGAGCAAAGTTATTTAAATGAGTTAGT 6411
Qy      6430  TGAGTTGGATGAGAATTGTTTGAGGTTTGTGTGCTAGAGAACAATAATAAAATAATTCTTT 6489
        |||||
Db      6412  TGAGTTGGATGAGAATTGTTTGAGGTTTGTGTGCTAGAGAACAATAATAAAATAATTCTTT 6471
Qy      6490  TTCAGAAAATATTTAATTTCTTCATAAAAAATAAGTTAAATATTTTTTTAAATATGTATAT 6549
        |||||
Db      6472  TTCAGAAAATATTTAATTTCTTCATAAAAAATAAGTTAAATATTTTTTTAAATATGTATAT 6531
Qy      6550  CTAATAGTACAAAATGGAATAAACATCATAGTGTATAGAAAACGAATTTGACAAGTTAA 6609
        |||||
Db      6532  CTAATAGTACAAAATGGAATAAACATCATAGTGTATAGAAAACGAATTTGACAAGTTAA 6591
Qy      6610  TGAATAAATGAACAAATGATTTTC 6632
        |||||
Db      6592  TGAATAAATGAACAAATGATTTTC 6614
```

LOCUS D86958 6614 bp mRNA linear PRI 22-AUG-1996

DEFINITION Human male myeloblast mRNA for KIAA0203 protein, complete cds.
ACCESSION D86958
VERSION D86958 GI:1503989
KEYWORDS KIAA0203 protein.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 6614)
AUTHORS Nomura,N.
TITLE Direct Submission
JOURNAL Submitted (02-AUG-1996) Nobuo Nomura, Kazusa DNA Research
Institute; 1532-3 Yanauchino, Kisarazu, Chiba 292, Japan
(E-mail:cdnainfo@kazusa.or.jp, Tel:0483-52-3930, Fax:0483-52-3931)
REFERENCE 2 (bases 1 to 6614)
AUTHORS Nagase,T., Seki,N., Ishikawa,K., Ohara,O. and Nomura,N.
TITLE Prediction of the coding sequences of unidentified human genes. VI.
The coding sequences of 80 new genes (KIAA 0201 - KIAA 0280)

Art Unit: 1642

deduced by analysis of cDNA clones from human cell line KG-1 and brain

JOURNAL Unpublished (1996)

FEATURES Location/Qualifiers

source 1..6614

/organism="Homo sapiens"

/mol_type="mRNA"

/db_xref="taxon:9606"

/chromosome="8"

/sex="male"

/cell_line="KG-1"

/cell_type="myeloblast"

S'UTR 1..515

gene 516..5291

/gene="KIAA0203"

CDS 516..5291

/gene="KIAA0203"

/note="The KIAA0203 protein has similarity to mouse CC1."

/citation=[2]

/codon_start=1

/product="KIAA0203 protein"

/protein_id="1503990"

/db_xref="GI:1503990"

/translation="MKLYVFLVNTGTTLTFTDELTVQTVADLKHAIQSKYKIAIQHV
LVVNGGECMAADRRVCTYSAGTDTNPIFLFNKEMILCDRPPAIPKTTFTSTENDMEIKV
EESLMMPAVFHTVASRTQLALEMYEVAKKLCSEGLVHDEHLQHQQWAAIMANLEDC
SNSYQKLLFKFESIYSNYLQSIEDIKLLKTLHGTAVSVMAKIPLLECLTRHSYRECLG
RLDSLPEHEDSEKAETKRSTELVLSPTMPRTTNESLLTSFPKSVEHVSPDTADAESGK
ETRESCQSTVHQDDETITDTKDGDLFFNVSLLDWINVQDRPNDVESLVRKCFDMSMR
LDPRIIRPFIAECRQTIAKLDNQNMKAIKGLEDRLYALDQMIASCGRLVNEQKELAQG
FLANQKRAENLKDASVLPDLCLSHANQLMIMLQNHRLKLLDIKQKCTTAKQELANNLHV
RLKWCCFVMLHADQDGEKLQALLRLVIELLERVKIVEALSTVPQMYCLAVVEVVRKM
FTKHREWAGALVKDGKRLYEAEKSKRESFGKLFKRSFLRNRLFRGLDSWPPSFCTQK
PRKFDCELPDISLQDLQFLQSFQSEVQPFLLRVPLLCDFEPLHQHVLALHNLVKAQGS
LDEMSQTTITDLLSEQKASVSQTSQSSASSPRMESTAGITTTTSPRTPPPLTVQDPLCP
AVCPLEELSPSIDAHTFDFETIPHPNIEQTIHQVSLDLDLSLAESPESDFMSAVNEFV
TEENLSSPNPIDPQSPPEMMVESLYSSVINAIIDSRMQDTNVCGKEDFGDHTSLNVQL
ERCRVVAQDSHFISIQTIKEDLCHFRFTFVQKEQCDFSNLSKCTAVEIRNIEKVKCSLE
ITLKEKHQKELSLKNEYEGKLDGLIKETEENENKIKKLGELVCLLEEVQNKDNEFA
LVKHEKEAVICLQNEKDQKLEMEMNIMHSQNCIEKELQKSREIVLEDLKKLHVENDEK
LQLLRAELQSLQSHLKELEDLQVRHIQEFKVMTDHRVSLLEELKKENQQIINQIQE
SHAEIIQEKEKQLQELKLVSDLSLTRCKLEVELALKEAETDEIKILLEESRAQQKET
LKSLEQETENLRTEISKLNQKIQDNNENYQVGLAELRLMTIEKDQCISELISRHEE
ESNILKAELNKVTSLHNQAFIEKNLKEQIIEQLSKLDSELSALERQKDEKITQQUEEK
YBAIIQNLKDRQKLVSSQEQDREQLIQKLNCEKDEAIQTALKEFKLEREVVEKELLE
KVKHLENQIAKSPAIDSTRGDSSSLVAELQEKLEEKAKFLEQLEEQEKRNEMQNV
RTSLIAEQQTNTFNTVLTREKMRKENIINDLSDKLKSTMQQQERDKDLIESLSEDRARL
LEEKKKLEEEVSKLRSSSFVSPYVATAPELYGACAPELPGESDRSAVETADEGRVDS
AMETSMMSVQENIHMLSEEKQRIMLLERTLQLKEEENKRLNQLMSQSMSSVSSRHSE
KIAIRDFQVGDVLVLIILDERHDNYVLFVTSPTLYFLHSESLPALDLKPASGASRRPWV
LGKVMKEYCYCAKKAQNRKFVPLGTGFYRVKAVSWNKKV"

S'UTR 5292..6614

ORIGIN

1	aacaaaccaa	gocgcggcgg	tgctcgcggc	cctgcgcgagc	cctcggcggt	gcctcagaat
61	ccccagtcg	cctgggcccc	tcggctctga	caggcgcgcg	cctctgtcc	ccgggcccc
121	gacccagagc	cgaggggccc	gctcgcgtcc	ttgtccgccc	ggacccctcc	ctgcctccta
181	gagttcgggg	ccgcgcgggg	cgggcgcccc	ggacgcggcg	ggttgtgtcg	gcttagcggt
241	gocgaatggg	cggttggtaa	ccgctgccga	ggactaggcg	gocgcgggaag	atgggtgccgg
301	gggtcgctgg	ctctgctgct	gccgcggcgg	aaggaggagg	cgttcgggt	ttctgagtt
361	taaccagtaa	tgccattcag	ttgccaatct	caagcaaaagc	aaacataagc	cagttttaat
421	ctacttttta	agaaaagtgg	tagtcctttt	cacagtgcct	gacgtaactg	tatcagaggg
481	tgaggatata	gctcacagaa	ttcagataaa	tcacatcatgaa	gttatatgta	tttctggtta
541	acactggaac	tactctaaca	tttgacaactg	aacttacagt	gcaaaactgtg	gcagaccta
601	agcatgccat	tcaaagcaaa	tacaagattg	ctattcaaca	ccaggtgctg	gtggccaatg
661	gaggagaatg	catggctgca	gatcgaagag	tgtgtaccta	cagtgtctggg	acggatacaa
721	atccaatttt	tcctttttaac	aaagaaatga	tccttatgtga	tcgtccacct	gctattccta
781	aaactacott	ttcgacagaa	aatgacatgg	aaataaaaagt	tgaagaatct	cttatgatgc

Art Unit: 1642

```

841 ctgcagtttt tcatactggt gottcaagga cacagcttgc attggaaatg tatgaagttg
901 ccaagaaaact ttgtttctttt tgtgaagggtc ttgtacatga tgaacatctt caacaccaag
961 gctggggtgc aatcatggcc aacctggagg actgttcaaa ttcatacca aagctacttt
1021 tcaagtttga aagtatttat tcaaatatc tgcagtccat agaagacatc aagttaaaac
1081 ttactcattt aggaactgca gtttcagtaa tggccaagat tccactgttg gactgcctaa
1141 ccagacatag ttacagagaa tgtttgggaa gactggattc tttacctgaa catgaagact
1201 cagaaaaaagc tgagacgaaa agatccactg aactgggtgc ctctcctgat atgcctagaa
1261 caactaacga atctttgtta acctcatttc ccaagtcagt ggaacatgtg tccccagata
1321 ccgcagatgc tgaaagtggc aaagaaatta gggaaatcttg tcaaagtact gttcatcagc
1381 aagatgaaac tacgattgac actaaagatg gtgatctgcc cttttttaat gtctctttgt
1441 tagactggat aaatgttcaa gatagacctc atgatgtgga atctttgtgc aggaagtgtc
1501 ttgattctat gaggcaggtt gatccaagga ttatcgacc atttatagca gaatgcctgc
1561 aaactattgc caaacttgat aatcagaata tgaaagccat taaaggactt gaagatcggc
1621 cccagccctt ggaccagatg attgttagct gtggccgact ggtgaatgaa cagaaagagc
1681 ttgctcaggg attttttagct aatcagaaga gagctgaaaa cttaaaggat gcactctgat
1741 taactgattt atgcctgagt cagcgaatc agttgatgat tatgttgcaa aatcatagaa
1801 aactgttaga tattaagcag aagtgtacca ctgccaacaa agaactagca aataacctac
1861 atgtcagact gaagtgtgtg tgccttgtaa tgcctcatgc tgatcaagat ggagagaagt
1921 tcaagctttt gctccgcctc gtaatagagc tgttagaaaag agtcaaaatt gttgaagctc
1981 ttagtacagt tctcagatg tactgcttag ctgttggtga ggttgtaaga agaaaaatgt
2041 tcataaaaaa ctacagggag tgggctgggtg ctttagtcaa agatggaaaag agattatatg
2101 aagcagaaaa atcaaaaagg gaatcctttg ggaattattt taggaagtct tttttaagaa
2161 atcgtctgtt tactgggactg gactcctggc ccccttccct ttgtactcaa aagcctcgaa
2221 agtttgactg tgaacttcca gatatttcat taaaagattt acagtttctg caatcatttt
2281 gtccctcgga agttcagcca ttccctcaggg ttcccttact ttgtgacttt gaacctctac
2341 accagcatgt acttgctcta cataatttgg taaaagcagc acaaagtttg gatgaaatgt
2401 cacagaccat tacagatcta ctgagtgaac aaaaggcctc tgtgagtcag acatccccc
2461 agtctgcttc ttcaccaagg atggaaagta cagcaggaat tacaactact acctaccga
2521 gaactcctcc accactgact gttcaggatc ccttatgtcc tgcagtttgt ccttagaag
2581 aattatctcc agatagtatt gatgcacata cgtttgattt tgaactattt ccccatccaa
2641 acatagaaca gactattcac caagtttctt tagacttgga ttcattagca gaaagtcttg
2701 aatcagattt tatgtctgct gtgaatgagt ttgtaataga agaaaatttg tctgtctcta
2761 atcctataag tgatccacaa agcccagaaa tgatgggtga atcactttat tcatcagtta
2821 tcaatgcgat agacagtaga cgaatgcagg atacaaatgt atgtggtaag gaggattttg
2881 gagatcacat tctctgtaat gtccagtttg aaagatgtag agttgttgcc caagactctc
2941 acttcagtat acaaaccatt aagggaagacc tttgccactt tagaacattt gtacaaaaag
3001 aaacagtgtg acttctcaaat tcattaaaat gtacagcagt agaaataaga aacattattg
3061 aaaaagtaaa atgttctctg gaaataaacac taaaagaaaa acatcaaaaa gaactactgt
3121 ctttaaaaaa tgataatgaa ggtaaaacttg acggaactat aaaggaaaact gaagagaatg
3181 aaaaacaaat taaaaaattg aagggaagagt tagtatgcct tgaggagggt ttacaaaata
3241 aagataatga atttgctttg gttaaacatg aaaaagaagc tgtaatctgc ctgcagaatg
3301 aaaaggatca gaagttgtta gagatggaaa atataatgca ctctcaaaat tgtgaaatta
3361 aagaaactgaa gcagtcacga gaaatagtgt tagaagactt aaaaaagctc catgttgaaa
3421 atgatgagaa gttacagtta ttgagggcag aacttcagtc cttggagcaa agtcatctaa
3481 aggaattaga ggacacactt caggttaggc acatacaaga gtttgagaag gttatgacag
3541 accacagagt ttctttggag gaattaaaaa aggaaaacca acaataattt aatcaaatc
3601 aagaatctca tgcctgaatt atccaggaaa aagaaaaaca gttacaggaa ttaaaactca
3661 aggtttctga tttgtcagac acgagatgca agttagaggt tgaacttgcg ttgaaggag
3721 cagaaaactg tgaaataaaa attttgctgg aagaaagcag agcccagcag aaggagacct
3781 tgaatctctt tcttgaacaa gagacagaaa atttgagaac agaaattagt aaactcaacc
3841 aaaagattca ggataataat gaaaattatc aggtgggctt agcagagcta agaactttaa
3901 tgacaattga aaaagatcag tgtatttccg agttaattag tagacatgaa gaagaatcta
3961 atatacttaa agctgaatta aacaaagtaa catctttgca taaccaagca ttgaaatag
4021 aaaaaaacct aaaaagacaa ataattgaac tgcagagtaa attggattca gaattgagtg
4081 ctcttgaaag acaaaaagat gaaaaaatta cccaacaaga agagaaatac gaagctatta
4141 tccagaacct tgagaaagac agacaaaaat tggtcagcag ccaggagcaa gacagagaa
4201 agttaattca gaagcttaat tgtgaaaaag atgaagctat tcagactgcc ctaaaagaat
4261 taaaattgga gagagaagtt gttgagaaag agttattaga aaaaagttaa catcttgaga
4321 atcaaatagc aaaaagtctt gccattgact ctaccagagg agattcttca agcttagttg
4381 ctgaacttca agaaaagctt caggaaagaaa aagctaagtt tctagaacaa cttgaagagc
4441 aagaaaaaag aaagaatgaa gaaatgcaaa atgttogaac atctttgatt gcggaacaa
4501 agaccaatth taacactgth ttaacaagag agaaaatgag aaaaagaaac ataataaatg
4561 atcttagtga taagttgaaa agtacaatgc agcaacaaga acgggataaa gatttgatag
4621 agtcactttg taagatcoga gctcgtttgc ttgaggaaaa gaaaaagctt gaagaagaa
4681 tcagtaagtt ggcagtagc agttttgttc cttcaccata ttagctaca gcccagaa
4741 tttatggagc ttgtgcacct gaactccag gtgaatcaga tagatccgt gtggaaacag
4801 cagatgaagg aagagtggat tcagcaatgg agacaagcat gatgtctgta caagaaaaa

```


Art Unit: 1642

```

4861 ttcatatgtt gtctgaagaa aaacagcgga taatgctgtt agaacgaaca ttgcaattga
4921 aagaagaaga aaataaaagg ttaaatcaaa gactgatgtc tcagagcatg tcttcagtat
4981 cttcaaggca ttctgaaaag atagctatta gagattttca ggtgggagat ttggtactca
5041 tcatoctaga cgaacgcoat gacaattatg tgttattttac tgttagtcoo actttatatt
5101 ttctacattc agagtctcta cctgcocctg atctcaaaoc agcttcaggt gcacttagaa
5161 gacocctggg actcggaaaa gtaatggaaa aagaatactg tcaagccaaa aaggcacaaa
5221 acagatttaa agttcctttg gggacaaaagt tttacagagt gaaagcogta tcoatggaata
5281 agaaagtata acttatggac aaaattaata cattctatga catttttttc tgatttgtoc
5341 tgcagtgtc attcatcact ccaaaaacag caggccatct ttttatgcaa aagtcacogt
5401 gacaatatac ttcactgggtg tacatcgttt actttttaac tggcttcatt ttaggaataa
5461 taaattoatc agaatccttg gctgaattaa aatgggtttt gtttttttgt tttttttttt
5521 acccagacaa ctctagaaat gcggacccaaa ctacttcatt ttctcaagg gcataccttg
5581 tgcattgtgg cttatgatga gccatattaa ttgctgttta aatatacact agcttgaaact
5641 tagatgttaa atgtttattat taccagcatt tgtccttttg tgaaatcagt atcagaatac
5701 ttgcactctt taacacattc tttataaaaat gtataaatta ttcagaacta tttaaaaata
5761 agaggagtgt tattgcatgc tgataatcat tttgagtttg cctcagtaga tactaaagca
5821 aattgtttca gtttttttaa atgccccttg atgtttcaaa aaaaaaaagg aactgtaatt
5881 tgattgaact attttaagat cagccataag taatcagcaa tcttcaaaag cactttcagt
5941 ggattgttca tctgggttct aaagggaaga gtctgtgcta ctaaccattt caaatgcaga
6001 ctcaaacctt cccaacatct ttatgactct agaataatca tattgatgaa atcgtaattc
6061 atggttgagt ttcagaacaa aagatattca ttgcacatta accattttaga ggtcatttaa
6121 ataacaaaat attgtattgt aaaagaactg tacaatttta aaacaataa gatttgaacc
6181 tgtaaattgt tgtgcctttt aaagaaggat acatttttaa tataatttgag tgattgctgg
6241 gaagtgtgaa aatattgtta tgtatcatat caaagagaaa catgtttatt acaaaaatgt
6301 tctttaacta tatactatgt aacagggtta acagtgttat gtagaataga attgtgtaaa
6361 ctagatcttt agagaagttg ccattgagca aagttattta aatgagttag ttgagttgga
6421 tgagaattgt ttgaggtttg ttgctagaga acaataataa aataattctt ttcagaaaa
6481 tatttaattt cttcataaaa ataagttaaa tattttttta aatatgtata tctaatagta
6541 caaatggaa taaacatcat agtgtataga aaactgaatt tgacaagtta atgaataaat
6601 gaacaaatga tttc

```

//


Blast 2 Sequences results

[PubMed](#)
[Entrez](#)
[BLAST](#)
[OMIM](#)
[Taxonomy](#)
[Structure](#)

BLAST 2 SEQUENCES RESULTS VERSION BLASTP 2.2.18 [Mar-02-2008]

Matrix: gap open: gap extension:

x_dropoff: expect: wordsize: Filter ☐ View option:

Masking character option: Masking color option:

☐ Show CDS translation

Sequence 1: gi|40788906|KIAA0203 [Homo sapiens]


Length = 1593 (1 .. 1593)

Sequence 2: gi|119607126|RB1-inducible coiled-coil 1, isoform CRA_b [Homo sapiens]

>gi|168272926|dbj|BAG10302.1| RB1-inducible coiled-coil protein 1 [synthetic construct]

Art Unit: 1642

Length = 1591 (1 .. 1591)



NOTE: Bitscore and expect value are calculated based on the size of the nr database.

J

Score = 3112 bits (8067), Expect = 0.0
 Identities = 1591/1591 (100%), Positives = 1591/1591 (100%), Gaps = 0/1591 (0%)

Query	3	MKLYVFLVNTGTTTLTFDTELTVQTVADLKHAIQSKYKIAIQHQVLVVGGECAADRRVC	62
		MKLYVFLVNTGTTTLTFDTELTVQTVADLKHAIQSKYKIAIQHQVLVVGGECAADRRVC	
Sbjct	1	MKLYVFLVNTGTTTLTFDTELTVQTVADLKHAIQSKYKIAIQHQVLVVGGECAADRRVC	60
Query	63	TYSAGTDTNPIFLFNKEMILCDRPPAIPKTTTFSTENDMEIKVEESLMMPAVFHTVASRTQ	122
		TYSAGTDTNPIFLFNKEMILCDRPPAIPKTTTFSTENDMEIKVEESLMMPAVFHTVASRTQ	
Sbjct	61	TYSAGTDTNPIFLFNKEMILCDRPPAIPKTTTFSTENDMEIKVEESLMMPAVFHTVASRTQ	120
Query	123	LALEMYEVAKKLCSEGLVHDEHLQHQQGWAAIMANLEDCSNSYQKLLFKFESIYSNYLQ	182
		LALEMYEVAKKLCSEGLVHDEHLQHQQGWAAIMANLEDCSNSYQKLLFKFESIYSNYLQ	
Sbjct	121	LALEMYEVAKKLCSEGLVHDEHLQHQQGWAAIMANLEDCSNSYQKLLFKFESIYSNYLQ	180
Query	183	SIEDIKLKLTHLGTAVSVMAKIPLLECLTRHSYRECLGRDLSLPEHEDSEKAETKRSTEL	242
		SIEDIKLKLTHLGTAVSVMAKIPLLECLTRHSYRECLGRDLSLPEHEDSEKAETKRSTEL	
Sbjct	181	SIEDIKLKLTHLGTAVSVMAKIPLLECLTRHSYRECLGRDLSLPEHEDSEKAETKRSTEL	240
Query	243	VLSPDMPRTTNESLLTSFPKSVEHVSPDTADAESGKEIRESCQSTVHQQDETTIDTKDGD	302
		VLSPDMPRTTNESLLTSFPKSVEHVSPDTADAESGKEIRESCQSTVHQQDETTIDTKDGD	
Sbjct	241	VLSPDMPRTTNESLLTSFPKSVEHVSPDTADAESGKEIRESCQSTVHQQDETTIDTKDGD	300
Query	303	LPFFNVSLLDWINVQDRPNVDES LVRKCFDMSRLDPRIIRPFIAECRQTI AKLDNQNMK	362
		LPFFNVSLLDWINVQDRPNVDES LVRKCFDMSRLDPRIIRPFIAECRQTI AKLDNQNMK	
Sbjct	301	LPFFNVSLLDWINVQDRPNVDES LVRKCFDMSRLDPRIIRPFIAECRQTI AKLDNQNMK	360
Query	363	AIKGLEDRLYALDQMIASCGRLVNEQKELAQGFLANQKRAENLKDASVLPDLCLSHANQL	422
		AIKGLEDRLYALDQMIASCGRLVNEQKELAQGFLANQKRAENLKDASVLPDLCLSHANQL	
Sbjct	361	AIKGLEDRLYALDQMIASCGRLVNEQKELAQGFLANQKRAENLKDASVLPDLCLSHANQL	420
Query	423	MIMLQNRKLLDIKQKCTTAKQELANNLHVRLKWCCFVMLHADQDGEKLQALLRLVIELL	482
		MIMLQNRKLLDIKQKCTTAKQELANNLHVRLKWCCFVMLHADQDGEKLQALLRLVIELL	
Sbjct	421	MIMLQNRKLLDIKQKCTTAKQELANNLHVRLKWCCFVMLHADQDGEKLQALLRLVIELL	480
Query	483	ERVKIVEALSTVPQMYCLAVVEVRRKMF IKHYREWAGALVKDGKRLYEAEKSKRESFGK	542
		ERVKIVEALSTVPQMYCLAVVEVRRKMF IKHYREWAGALVKDGKRLYEAEKSKRESFGK	
Sbjct	481	ERVKIVEALSTVPQMYCLAVVEVRRKMF IKHYREWAGALVKDGKRLYEAEKSKRESFGK	540
Query	543	LFRKSFLNRNRLFRGLDSWPPSFCTQKPRKFDCELPDISLKDQLQSFQFCPSEVQPFLRVP	602

Art Unit: 1642

Sbjct	541	LFRKSFLRNRLFRGLDSWPPSFCTQKPRKFDCELPDISLKDLQFLQSFPCSEVQPFLRVP LFRKSFLRNRLFRGLDSWPPSFCTQKPRKFDCELPDISLKDLQFLQSFPCSEVQPFLRVP	600
Query	603	LLCDFEPLHQHVLAHLNHLVKAQSLDEMSQTITDLLSEQKASVSQTSPQSASSPRMESTA LLCDFEPLHQHVLAHLNHLVKAQSLDEMSQTITDLLSEQKASVSQTSPQSASSPRMESTA	662
Sbjct	601	LLCDFEPLHQHVLAHLNHLVKAQSLDEMSQTITDLLSEQKASVSQTSPQSASSPRMESTA LLCDFEPLHQHVLAHLNHLVKAQSLDEMSQTITDLLSEQKASVSQTSPQSASSPRMESTA	660
Query	663	GITTTTSPRTPPPLTVQDPLCPAVCPLEELSPDSIDAHTFDFETIPHPNIEQTIHQVSLD GITTTTSPRTPPPLTVQDPLCPAVCPLEELSPDSIDAHTFDFETIPHPNIEQTIHQVSLD	722
Sbjct	661	GITTTTSPRTPPPLTVQDPLCPAVCPLEELSPDSIDAHTFDFETIPHPNIEQTIHQVSLD GITTTTSPRTPPPLTVQDPLCPAVCPLEELSPDSIDAHTFDFETIPHPNIEQTIHQVSLD	720
Query	723	LDSLAESEPESDFMSAVNEFVIEENLSSPNPISDPQSPPEMMVESLYSSVINAIDSRMQDT LDSLAESEPESDFMSAVNEFVIEENLSSPNPISDPQSPPEMMVESLYSSVINAIDSRMQDT	782
Sbjct	721	LDSLAESEPESDFMSAVNEFVIEENLSSPNPISDPQSPPEMMVESLYSSVINAIDSRMQDT LDSLAESEPESDFMSAVNEFVIEENLSSPNPISDPQSPPEMMVESLYSSVINAIDSRMQDT	780
Query	783	NVCGKEDFGDHTSLNVQLERCRVVAQDSHFSIQTIKEDLCHFRFTVQKEQCDFNSLKCT NVCGKEDFGDHTSLNVQLERCRVVAQDSHFSIQTIKEDLCHFRFTVQKEQCDFNSLKCT	842
Sbjct	781	NVCGKEDFGDHTSLNVQLERCRVVAQDSHFSIQTIKEDLCHFRFTVQKEQCDFNSLKCT NVCGKEDFGDHTSLNVQLERCRVVAQDSHFSIQTIKEDLCHFRFTVQKEQCDFNSLKCT	840
Query	843	AVEIRNIEKVCSLEITLKEKHQKELLSLKNEYEGKLDGLIKETEENENKIKKLKSELV AVEIRNIEKVCSLEITLKEKHQKELLSLKNEYEGKLDGLIKETEENENKIKKLKSELV	902
Sbjct	841	AVEIRNIEKVCSLEITLKEKHQKELLSLKNEYEGKLDGLIKETEENENKIKKLKSELV AVEIRNIEKVCSLEITLKEKHQKELLSLKNEYEGKLDGLIKETEENENKIKKLKSELV	900
Query	903	CLEEVQLQNKDNEFALVKHEKEAVICLQNEKDQKLEMEMIMHSQNCIEKELKQSRIVLE CLEEVQLQNKDNEFALVKHEKEAVICLQNEKDQKLEMEMIMHSQNCIEKELKQSRIVLE	962
Sbjct	901	CLEEVQLQNKDNEFALVKHEKEAVICLQNEKDQKLEMEMIMHSQNCIEKELKQSRIVLE CLEEVQLQNKDNEFALVKHEKEAVICLQNEKDQKLEMEMIMHSQNCIEKELKQSRIVLE	960
Query	963	DLKKLHVENDEKLQLLRAELQSLEQSHLKELEDTLQVRHIQEFKVMTDHRVSLEELKKE DLKKLHVENDEKLQLLRAELQSLEQSHLKELEDTLQVRHIQEFKVMTDHRVSLEELKKE	1022
Sbjct	961	DLKKLHVENDEKLQLLRAELQSLEQSHLKELEDTLQVRHIQEFKVMTDHRVSLEELKKE DLKKLHVENDEKLQLLRAELQSLEQSHLKELEDTLQVRHIQEFKVMTDHRVSLEELKKE	1020
Query	1023	NQQIINQIQESHAEIIQEKEKQLQELKLVSDLSLTRCKLEVELALKEAETDEIKILLEE NQQIINQIQESHAEIIQEKEKQLQELKLVSDLSLTRCKLEVELALKEAETDEIKILLEE	1082
Sbjct	1021	NQQIINQIQESHAEIIQEKEKQLQELKLVSDLSLTRCKLEVELALKEAETDEIKILLEE NQQIINQIQESHAEIIQEKEKQLQELKLVSDLSLTRCKLEVELALKEAETDEIKILLEE	1080
Query	1083	SRAQQKETLKSLEQETENLRTEISKLNQKIQDNNENYQVGLAELRTLMTIEKDQCISEL SRAQQKETLKSLEQETENLRTEISKLNQKIQDNNENYQVGLAELRTLMTIEKDQCISEL	1142
Sbjct	1081	SRAQQKETLKSLEQETENLRTEISKLNQKIQDNNENYQVGLAELRTLMTIEKDQCISEL SRAQQKETLKSLEQETENLRTEISKLNQKIQDNNENYQVGLAELRTLMTIEKDQCISEL	1140
Query	1143	ISRHEEESNILKAELNKVTSLHNQAFEIEKNLKEQIIELQSKLDSELSALERQKDEKITQ ISRHEEESNILKAELNKVTSLHNQAFEIEKNLKEQIIELQSKLDSELSALERQKDEKITQ	1202
Sbjct	1141	ISRHEEESNILKAELNKVTSLHNQAFEIEKNLKEQIIELQSKLDSELSALERQKDEKITQ ISRHEEESNILKAELNKVTSLHNQAFEIEKNLKEQIIELQSKLDSELSALERQKDEKITQ	1200
Query	1203	QEEKYEAIIQNLEKDRQKLVSSQEQRDREQLIQKLNCEKDEAIQTALKEFKLEREVVEKEL QEEKYEAIIQNLEKDRQKLVSSQEQRDREQLIQKLNCEKDEAIQTALKEFKLEREVVEKEL	1262
Sbjct	1201	QEEKYEAIIQNLEKDRQKLVSSQEQRDREQLIQKLNCEKDEAIQTALKEFKLEREVVEKEL QEEKYEAIIQNLEKDRQKLVSSQEQRDREQLIQKLNCEKDEAIQTALKEFKLEREVVEKEL	1260
Query	1263	LEKVKHLENQIAKSPAIDSTRGDSSSLVAELQEKLQEEKAKFLEQLEEQEKRKNEEMQNV LEKVKHLENQIAKSPAIDSTRGDSSSLVAELQEKLQEEKAKFLEQLEEQEKRKNEEMQNV	1322
Sbjct	1261	LEKVKHLENQIAKSPAIDSTRGDSSSLVAELQEKLQEEKAKFLEQLEEQEKRKNEEMQNV LEKVKHLENQIAKSPAIDSTRGDSSSLVAELQEKLQEEKAKFLEQLEEQEKRKNEEMQNV	1320
Query	1323	RTSLIAEQQTNFNTVLTREKMRKENIINDLSDKLKSTMQQQERDKDLIESLSEDRARLLE RTSLIAEQQTNFNTVLTREKMRKENIINDLSDKLKSTMQQQERDKDLIESLSEDRARLLE	1382
Sbjct	1321	RTSLIAEQQTNFNTVLTREKMRKENIINDLSDKLKSTMQQQERDKDLIESLSEDRARLLE RTSLIAEQQTNFNTVLTREKMRKENIINDLSDKLKSTMQQQERDKDLIESLSEDRARLLE	1380
Query	1383	EKKKLEEEVSKLRSSSFVSPYVATAPELYGACAPELPGESDRSAVETADEGRVDSAMET EKKKLEEEVSKLRSSSFVSPYVATAPELYGACAPELPGESDRSAVETADEGRVDSAMET	1442
Sbjct	1381	EKKKLEEEVSKLRSSSFVSPYVATAPELYGACAPELPGESDRSAVETADEGRVDSAMET EKKKLEEEVSKLRSSSFVSPYVATAPELYGACAPELPGESDRSAVETADEGRVDSAMET	1440
Query	1443	SMMSVQENIHMLSEEKQRIIMLLERTLQLKEEENKRLNQRLMSQSMSSVSSRHSEKIAIRD SMMSVQENIHMLSEEKQRIIMLLERTLQLKEEENKRLNQRLMSQSMSSVSSRHSEKIAIRD	1502
Sbjct	1441	SMMSVQENIHMLSEEKQRIIMLLERTLQLKEEENKRLNQRLMSQSMSSVSSRHSEKIAIRD SMMSVQENIHMLSEEKQRIIMLLERTLQLKEEENKRLNQRLMSQSMSSVSSRHSEKIAIRD	1500
Query	1503	FQVGDLVLIILDERHDNYVLFVTSPTLYFLHSESLPALDLKPASGASRRPWVLGKVMEKE FQVGDLVLIILDERHDNYVLFVTSPTLYFLHSESLPALDLKPASGASRRPWVLGKVMEKE	1562
Sbjct	1501	FQVGDLVLIILDERHDNYVLFVTSPTLYFLHSESLPALDLKPASGASRRPWVLGKVMEKE FQVGDLVLIILDERHDNYVLFVTSPTLYFLHSESLPALDLKPASGASRRPWVLGKVMEKE	1560

Art Unit: 1642

```
Query 1563 YCQAKKAQNRFKVPLGTKFYRVKAVSWNKKV 1593
          YCQAKKAQNRFKVPLGTKFYRVKAVSWNKKV
Sbjct 1561 YCQAKKAQNRFKVPLGTKFYRVKAVSWNKKV 1591
```

```
CPU time:      0.04 user secs.          0.03 sys. secs      0.07 total secs.
```